vs
Side-by-side financial comparison of SOMNIGROUP INTERNATIONAL INC. (SGI) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.9B, roughly 1.3× SOMNIGROUP INTERNATIONAL INC.). Zoetis runs the higher net margin — 25.3% vs 7.5%, a 17.7% gap on every dollar of revenue. On growth, SOMNIGROUP INTERNATIONAL INC. posted the faster year-over-year revenue change (54.7% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $41.1M). Over the past eight quarters, SOMNIGROUP INTERNATIONAL INC.'s revenue compounded faster (25.3% CAGR vs 4.4%).
Somnigroup International Inc. is an American manufacturer of mattresses and bedding products.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
SGI vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $2.4B |
| Net Profit | $140.8M | $603.0M |
| Gross Margin | 44.0% | 70.2% |
| Operating Margin | 13.2% | 31.9% |
| Net Margin | 7.5% | 25.3% |
| Revenue YoY | 54.7% | 3.0% |
| Net Profit YoY | 95.8% | 3.8% |
| EPS (diluted) | $0.71 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9B | $2.4B | ||
| Q3 25 | $2.1B | $2.4B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | $1.6B | $2.2B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.2B | $2.4B | ||
| Q1 24 | $1.2B | $2.2B |
| Q4 25 | $140.8M | $603.0M | ||
| Q3 25 | $177.4M | $721.0M | ||
| Q2 25 | $99.0M | $718.0M | ||
| Q1 25 | $-33.1M | $631.0M | ||
| Q4 24 | $71.9M | $581.0M | ||
| Q3 24 | $130.0M | $682.0M | ||
| Q2 24 | $106.1M | $624.0M | ||
| Q1 24 | $76.3M | $599.0M |
| Q4 25 | 44.0% | 70.2% | ||
| Q3 25 | 44.9% | 71.5% | ||
| Q2 25 | 44.0% | 73.6% | ||
| Q1 25 | 36.2% | 72.0% | ||
| Q4 24 | 43.3% | 69.5% | ||
| Q3 24 | 45.4% | 70.6% | ||
| Q2 24 | 44.9% | 71.7% | ||
| Q1 24 | 43.1% | 70.6% |
| Q4 25 | 13.2% | 31.9% | ||
| Q3 25 | 14.8% | 37.0% | ||
| Q2 25 | 9.6% | 36.7% | ||
| Q1 25 | 0.8% | 36.5% | ||
| Q4 24 | 10.6% | 31.6% | ||
| Q3 24 | 15.5% | 36.6% | ||
| Q2 24 | 14.0% | 33.0% | ||
| Q1 24 | 11.1% | 34.1% |
| Q4 25 | 7.5% | 25.3% | ||
| Q3 25 | 8.4% | 30.0% | ||
| Q2 25 | 5.3% | 29.2% | ||
| Q1 25 | -2.1% | 28.4% | ||
| Q4 24 | 6.0% | 25.1% | ||
| Q3 24 | 10.0% | 28.6% | ||
| Q2 24 | 8.6% | 26.4% | ||
| Q1 24 | 6.4% | 27.4% |
| Q4 25 | $0.71 | $1.37 | ||
| Q3 25 | $0.83 | $1.63 | ||
| Q2 25 | $0.47 | $1.61 | ||
| Q1 25 | $-0.17 | $1.41 | ||
| Q4 24 | $0.40 | $1.29 | ||
| Q3 24 | $0.73 | $1.50 | ||
| Q2 24 | $0.60 | $1.37 | ||
| Q1 24 | $0.43 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $3.1B | $3.3B |
| Total Assets | $11.6B | $15.5B |
| Debt / EquityLower = less leverage | 1.47× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.8B | — | ||
| Q1 25 | $4.9B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.5B | — |
| Q4 25 | $3.1B | $3.3B | ||
| Q3 25 | $3.0B | $5.4B | ||
| Q2 25 | $2.8B | $5.0B | ||
| Q1 25 | $2.7B | $4.7B | ||
| Q4 24 | $559.0M | $4.8B | ||
| Q3 24 | $564.5M | $5.2B | ||
| Q2 24 | $411.8M | $5.0B | ||
| Q1 24 | $326.6M | $5.1B |
| Q4 25 | $11.6B | $15.5B | ||
| Q3 25 | $11.4B | $15.2B | ||
| Q2 25 | $11.4B | $14.5B | ||
| Q1 25 | $11.3B | $14.1B | ||
| Q4 24 | $6.0B | $14.2B | ||
| Q3 24 | $4.6B | $14.4B | ||
| Q2 24 | $4.6B | $14.2B | ||
| Q1 24 | $4.6B | $14.3B |
| Q4 25 | 1.47× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 1.79× | — | ||
| Q4 24 | 6.69× | — | ||
| Q3 24 | 3.95× | — | ||
| Q2 24 | 5.92× | — | ||
| Q1 24 | 7.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.4M | $893.0M |
| Free Cash FlowOCF − Capex | $41.1M | $732.0M |
| FCF MarginFCF / Revenue | 2.2% | 30.7% |
| Capex IntensityCapex / Revenue | 3.1% | 6.7% |
| Cash ConversionOCF / Net Profit | 0.71× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $633.2M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.4M | $893.0M | ||
| Q3 25 | $408.2M | $938.0M | ||
| Q2 25 | $186.1M | $486.0M | ||
| Q1 25 | $106.4M | $587.0M | ||
| Q4 24 | $129.1M | $905.0M | ||
| Q3 24 | $256.6M | $951.0M | ||
| Q2 24 | $150.6M | $502.0M | ||
| Q1 24 | $130.2M | $595.0M |
| Q4 25 | $41.1M | $732.0M | ||
| Q3 25 | $360.3M | $805.0M | ||
| Q2 25 | $149.4M | $308.0M | ||
| Q1 25 | $82.4M | $438.0M | ||
| Q4 24 | $108.2M | $689.0M | ||
| Q3 24 | $240.2M | $784.0M | ||
| Q2 24 | $122.1M | $370.0M | ||
| Q1 24 | $98.7M | $455.0M |
| Q4 25 | 2.2% | 30.7% | ||
| Q3 25 | 17.0% | 33.5% | ||
| Q2 25 | 7.9% | 12.5% | ||
| Q1 25 | 5.1% | 19.7% | ||
| Q4 24 | 9.0% | 29.7% | ||
| Q3 24 | 18.5% | 32.8% | ||
| Q2 24 | 9.9% | 15.7% | ||
| Q1 24 | 8.3% | 20.8% |
| Q4 25 | 3.1% | 6.7% | ||
| Q3 25 | 2.3% | 5.5% | ||
| Q2 25 | 2.0% | 7.2% | ||
| Q1 25 | 1.5% | 6.7% | ||
| Q4 24 | 1.7% | 9.3% | ||
| Q3 24 | 1.3% | 7.0% | ||
| Q2 24 | 2.3% | 5.6% | ||
| Q1 24 | 2.6% | 6.4% |
| Q4 25 | 0.71× | 1.48× | ||
| Q3 25 | 2.30× | 1.30× | ||
| Q2 25 | 1.88× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 1.80× | 1.56× | ||
| Q3 24 | 1.97× | 1.39× | ||
| Q2 24 | 1.42× | 0.80× | ||
| Q1 24 | 1.71× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SGI
| Mattress Firm Segment | $892.1M | 48% |
| Tempur Sealy North America Segment | $620.5M | 33% |
| Tempur Sealy International Segment | $355.8M | 19% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
